I agree most with this post. I thought that at ASCO we couldn't present results anyway, so it's not going to be there that CTIX makes the big splash and says "it works". I could see that a PR is released just before ASCO that gives data and indicates p53 activation so that during the ASCO presentation they can introduce Kevetrin as "the drug that non-toxically activates p53", and leverage the momentum in the scientific community. However, such a PR will be a pleasant surprise. I think BigJeff is likely right that Dana Farber will release the data in the Q4 when the trial is over. Things never move as fast as they seem...
In response to:
They become well informed when news gets out, especially of this magnitude. I have not said a word about ASCO, nor do I have any expectations for it. Investors will get news when Leo and Dana Farber want to release it. I would not be surprised if we don't get a full picture until the conclusion of Phase 1 in the 4th quarter. I am more tempered then most . . . the science, discovery, business processes, breakthrough, comes way before share price value . . . although that will come in time.